Xi-Yu Cheng

Reprogramming the therapeutic fate of living biotherapeutic products for intestinal diseases via biomaterials.

Live biotherapeutic products (LBP) hold great promise for the treatment of intestinal diseases such as inflammatory bowel disease and colorectal cancer, owing to their unique abilities to modulate the gut microbiota, regulate host immunity, and influence drug metabolism. However, the use of natural strains remains cons...